![](https://www.mitacs.ca/wp-content/uploads/2023/12/generic-logo-background.png)
IMV Inc. is developing injectable cancer immune therapy using the company’s DPXTM technology. DPX is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect). DPX can be tailored to various cancers via the use of tumor specific components in the formula. The way by which this therapy exerts […]
Read More